Skip to main navigation Skip to search Skip to main content

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action

  • Mario A. Eisenberger*
  • , Menachem Laufer
  • , Nicholas J. Vogelzang
  • , Oliver Sartor
  • , Donald Thornton
  • , Blake Lee Neubauer
  • , Victoria Sinibaldi
  • , Gary Lieskovsky
  • , Michael A. Carducci
  • , Mariana Zahurak
  • , Derek Raghavan
    • *Corresponding author for this work
  • Johns Hopkins University

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science